SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, BCMA, CAR-T, CD19, TCR

February 24, 2023

Clinical Results from P-MUC1C-ALLO1 and P-BCMA-ALLO1; Novel Allogeneic CAR-T (P-ckit-ALLO1) for AML; Upcoming Milestones for Poseida; Poseida’s R&D Day Summary

Here is a brief preview of this blast: On Wednesday, February 22, Poseida held its R&D day (press release / presentation) highlighting clinical results from P-MUC1C-ALLO1 (allogeneic MUC1-C CAR-T) in solid tumors and P-BCMA-ALLO1 (allogeneic BCMA CAR-T) for r/r MM. Additionally, management noted that P-CD19CD20-ALLO1’s (allogeneic CD19 x CD20 CAR-T) IND filing is expected in mid-2023 and presented a novel allogeneic CAR-T (P-ckit-ALLO1) for AML. Below, Celltelligence provides insights on Poseida’s clinical results, while discussing the potential of its more novel allogeneic assets.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.